Group Gp Lp Column III Buys 18,052 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III purchased 18,052 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The stock was acquired at an average cost of $19.60 per share, with a total value of $353,819.20. Following the transaction, the insider directly owned 1,016,658 shares of the company’s stock, valued at approximately $19,926,496.80. This represents a 1.81% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Friday, January 16th, Group Gp Lp Column III purchased 2,562 shares of Surrozen stock. The shares were acquired at an average cost of $20.00 per share, with a total value of $51,240.00.
• On Thursday, January 15th, Group Gp Lp Column III acquired 11,893 shares of Surrozen stock. The shares were purchased at an average cost of $19.89 per share, for a total transaction of $236,551.77.
• On Wednesday, January 14th, Group Gp Lp Column III purchased 5,523 shares of Surrozen stock. The shares were purchased at an average cost of $19.99 per share, for a total transaction of $110,404.77.
• On Tuesday, January 13th, Group Gp Lp Column III bought 12,470 shares of Surrozen stock. The stock was acquired at an average cost of $19.80 per share, for a total transaction of $246,906.00.
• On Tuesday, January 6th, Group Gp Lp Column III purchased 15,100 shares of Surrozen stock. The shares were acquired at an average price of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Group Gp Lp Column III purchased 30,884 shares of Surrozen stock. The shares were acquired at an average cost of $19.54 per share, with a total value of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III acquired 5,266 shares of Surrozen stock. The stock was acquired at an average cost of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III bought 315,457 shares of Surrozen stock. The shares were acquired at an average cost of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Price Performance

Shares of Surrozen stock traded down $2.02 on Tuesday, hitting $17.98. 62,608 shares of the company’s stock traded hands, compared to its average volume of 59,333. The firm’s 50-day moving average price is $18.98 and its two-hundred day moving average price is $14.13. The stock has a market capitalization of $154.09 million, a PE ratio of -0.80 and a beta of 0.58. Surrozen, Inc. has a one year low of $5.90 and a one year high of $24.94.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings data on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The company had revenue of $0.98 million for the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. On average, analysts forecast that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on SRZN shares. Wall Street Zen raised shares of Surrozen to a “sell” rating in a research report on Friday, November 28th. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Institutional Trading of Surrozen

Several hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC raised its stake in Surrozen by 32.8% in the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after purchasing an additional 5,702 shares during the last quarter. Armistice Capital LLC acquired a new position in shares of Surrozen during the 2nd quarter worth $536,000. Woodline Partners LP bought a new stake in shares of Surrozen during the 3rd quarter worth $621,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Surrozen in the third quarter valued at about $889,000. 66.57% of the stock is owned by institutional investors and hedge funds.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.